1059 related articles for article (PubMed ID: 31795559)
1. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
2. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
3. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
[TBL] [Abstract][Full Text] [Related]
6. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
Yeung TW; Cheong KN; Lau YL; Tse KN
Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
[TBL] [Abstract][Full Text] [Related]
7. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review.
Nishi K; Ogura M; Tamai N; Gima M; Ide K; Koinuma G; Kamei K; Ito S
Pediatr Rheumatol Online J; 2022 Aug; 20(1):60. PubMed ID: 35927666
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
11. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
13. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease].
Zou RY; Zhao Q; Tian YQ; Yan X; Qiu XH; Gao YJ; Liu Y; Huang M; Cao M; Dai JH; Cai HR
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):781-790. PubMed ID: 37536988
[No Abstract] [Full Text] [Related]
15. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
[TBL] [Abstract][Full Text] [Related]
16. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
[TBL] [Abstract][Full Text] [Related]
17. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
18. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
[TBL] [Abstract][Full Text] [Related]
19. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
20. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
